Biomay AG, of Vienna, said a landmark phase IIb study has been successfully completed with its third-generation grass pollen allergy vaccine BM32. In this placebo-controlled, double-blind, prospective study, 181 patients were included and initially received either of two doses of BM32 or the matching placebo.